培训课件_瑞舒伐他汀的代谢途径以及安全性.pptVIP

Objectives We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease (CKD). Background Whether patents with moderate CKD (estimated glomerular filtration rate [eGFR] 60 ml/min/1.73 m2) benefit from statin therapy is uncertain, particularly among those without hyperlipidemia or known cardiovascular disease. Methods Within the JUPITER (Justification for the Use of statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) primary prevention trial of rosuvastatin 20 mg compared with placebo among men and women free of cardio